Compare TBBK & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | EVO |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 895.8M |
| IPO Year | 2005 | N/A |
| Metric | TBBK | EVO |
|---|---|---|
| Price | $55.38 | $2.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $69.00 | $7.00 |
| AVG Volume (30 Days) | ★ 451.9K | 107.5K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.69 | N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $141,147,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.90 | $7.13 |
| P/E Ratio | $11.14 | ★ N/A |
| Revenue Growth | ★ 20.85 | N/A |
| 52 Week Low | $40.51 | $2.31 |
| 52 Week High | $81.65 | $4.80 |
| Indicator | TBBK | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 45.13 |
| Support Level | $55.14 | $2.32 |
| Resistance Level | $71.63 | $3.82 |
| Average True Range (ATR) | 1.65 | 0.07 |
| MACD | 0.59 | 0.05 |
| Stochastic Oscillator | 93.29 | 98.11 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.